ASP
APLS

Adams Street Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Adams Street Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-36,194
Closed -$796K – 14
2018
Q2 		$796K Buy
+36,194
New +$832K 0.12% 10

Other funds holding APLS

HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adams Street Partners's APLS Position: Q3 2018 in Review

Adams Street Partners sold out of Apellis Pharmaceuticals (APLS) in Q3 2018, closing a stake of 36,194 shares — an estimated $796K sold.

Adams Street Partners first reported a position in APLS in Q2 2018 and held it in 1 quarter. The position peaked at $796K in Q2 2018. 79 funds tracked by Wall St. Rank hold APLS as of Q3 2018.

  • Adams Street Partners reported no remaining Apellis Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Adams Street Partners sold 36,194 Apellis Pharmaceuticals shares in Q3 2018, an estimated $796K.
  • Adams Street Partners first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Adams Street Partners's Apellis Pharmaceuticals position peaked at $796K in Q2 2018.
  • 79 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2018.

Based on Adams Street Partners's 13F filing for Q3 2018, filed 14 Nov 2018.